4-(1-pyrrolidinylsulfonyl)-10-azatricyclo[6.3.1.02,7]-dodeca-2(7),3,5-triene | 357425-57-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 4-(1-pyrrolidinylsulfonyl)-10-azatricyclo[6.3.1.02,7]-dodeca-2(7),3,5-triene
• 英文别名: 4-Pyrrolidin-1-ylsulfonyl-10-azatricyclo[6.3.1.02,7]dodeca-2(7),3,5-triene
• CAS: 357425-57-1
• 化学式: C₁₅H₂₀N₂O₂S
• 分子量: 292.402
• InChiKey: ZAJOQFQUHOWCFD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  57.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic componunds
  申请人：——

  公开号：US20030060624A1

  公开（公告）日：2003-03-27

  The present invention relates to processes for the preparation of any of the intermediate 1,3-substituted indenes of the formulae (Ia), (Ib) and (Ic) or a mixture thereof: 1 wherein R 1 , R 2 , R 3 , R 4 , and R 5 are defined herein. Compounds of formulae (Ia), (Ib) and (IC) or mixtures thereof are useful in the preparation of compounds of formula (II): 2 wherein R 2 , R 3 and R 6 are also defined herein.

  本发明涉及制备公式(Ia)、(Ib)和(Ic)中任一中间体1,3-取代吲哚的过程，或其混合物： 其中R1、R2、R3、R4和R5在此处定义。公式(Ia)、(Ib)和(Ic)或其混合物的化合物在制备公式(II)的化合物中有用： 其中R2、R3和R6也在此处定义。
• Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome
  申请人：Pfizer Inc.

  公开号：US20030134844A1

  公开（公告）日：2003-07-17

  This invention relates to the use of nicotinic acetylcholine receptor agonists for the treatment of restless legs syndrome (RLS). The invention further relates to the use of a nicotinic acetylcholine receptor agonist in the manufacture of a medicament for the treatment of RLS. The present invention also relates to a pharmaceutical composition for the treatment of RLS containing a nicotinic acetylcholine receptor agonist.

  这项发明涉及尼古丁型乙酰胆碱受体激动剂用于治疗不安腿综合征（RLS）。该发明还涉及尼古丁型乙酰胆碱受体激动剂在制造治疗RLS药物中的应用。本发明还涉及一种含有尼古丁型乙酰胆碱受体激动剂的治疗RLS的药物组合物。
• Aryl fused azapolycyclic compounds
  申请人：——

  公开号：US20030130260A1

  公开（公告）日：2003-07-10

  This invention is directed to compounds of the formula (I): 1 and their pharmaceutically acceptable salts, wherein R 1 , R 2 , and R 3 are as defined herein; intermediates for the synthesis of such compounds, pharmaceutical compositions containing such compounds; and methods of using such compounds in the treatment of neurological and psychological disorders.

  本发明涉及式(I)的化合物及其药学上可接受的盐，其中R1、R2和R3如本文所定义；用于合成此类化合物的中间体，含有此类化合物的药物组合物；以及使用此类化合物治疗神经和心理疾病的方法。
• Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
  申请人：Singer A. Robert

  公开号：US20060079707A1

  公开（公告）日：2006-04-13

  The present invention relates to processes for the preparation of any of the intermediate 1,3-substituted indenes of the formulae (Ia), (Ib) and (Ic) or a mixture thereof: wherein R 1 , R 2 , R 3 , R 4 , and R 5 are defined herein. Compounds of formulae (Ia), (Ib) and (Ic) or mixtures thereof are useful in the preparation of compounds of formula (II): wherein R 2 , R 3 and R 6 are also defined herein.

  本发明涉及制备公式(Ia)、(Ib)和(Ic)中任何一种或其混合物的中间体1,3-取代茚的过程：其中R1、R2、R3、R4和R5的定义如本文所述。 公式(Ia)、(Ib)和(Ic)或其混合物的化合物在制备公式(II)的化合物中有用：其中R2、R3和R6的定义也如本文所述。
• Therapeutic combination for cognititon enhancement and psychotic disorders
  申请人：Romano Joseph Steve

  公开号：US20050215571A1

  公开（公告）日：2005-09-29

  This invention relates to combinations of an atypical antipsychotic, and a nicotinic receptor agonist or antagonist, kits containing such combinations, pharmaceutical compositions comprising such combinations, and methods of using such combinations to treat patients suffering from cognitive impairment disorders or psychotic disorders or conditions.

  本发明涉及一种非典型抗精神病药和一种烟碱受体激动剂或拮抗剂的组合物、含有这种组合物的试剂盒、包含这种组合物的药物组合物以及使用这种组合物治疗患有认知障碍疾病或精神病的患者的方法。